文章预览
01 HAIC联合仑伐替尼治疗浸润性肝细胞癌的基础上联合免疫检查点抑制剂提高疗效：多中心回顾性研究 主要研究结果： • 纳入浸润性HCC，接受一线HAIC联合仑伐替尼(A)或HAIC联合仑伐替尼与PD-1抑制剂(B)(173/128) • 倾向评分配对(PSM)后：A组与B组的中位OS分别为14.1与16.1个月，中位PFS分别为4.6与7.5个月 • OS：HR=0.66; P=0.008 • PFS：HR=0.53; P < 0.001 • 无转移亚组：B组的OS无显著获益(HR=0.68; P=0.091) • 少(2-3个周期)与多(4-6个周期)HAIC的OS无差异(HR=0.99; P=0.938) 参考文献： Wang W, Li R, Li H, Wang M, Wang J, Wang X, Zhou Q. Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study. Immunotargets Ther. 2024 Aug 19;13:399-412. doi: 10.2147/ITT.S470797. PMID: 39184311; PMCID: PMC11342945. 02 慢性
………………………………
